ReviewResearch in veterinary science2020
The balancing act: Immunology of leishmaniosis.
Review in Research in veterinary science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- World Association for Veterinary Dermatology Consensus Statement for Diagnosis, and Evidence-Based Clinical Practice Guidelines for Treatment and Prevention of Canine Leishmaniosis.Veterinary dermatology · 2025Guideline
- LeishVet update and current recommendations on feline leishmaniosis.Parasites & vectors · 2026Review
- A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis.iScience · 2026Article
- Updated Canine Leishmaniosis Working Group recommendations for leishmaniosis in dogs: Q&A on clinical management.Parasites & vectors · 2026Review
- Article
- Leishmania infantum in red foxes (Vulpes vulpes): from clinical findings to cytokine expression.Parasites & vectors · 2026Article
- Hematological Ratios inAnimals : an open access journal from MDPI · 2026Article
- Ex vivo effects of oclacitinib and cyclosporin A on canine immune response to Leishmania infantum.Scientific reports · 2026Article
- The critical window for host defense: macrophage trogocytosis eliminatesFrontiers in immunology · 2026Article
- Revisiting visceral leishmaniasis in immunocompromised patients: Ongoing gaps and advances in diagnostics, therapies, and preventive measures.Current research in parasitology & vector-borne diseases · 2026Review
- A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis.bioRxiv : the preprint server for biology · 2025Article
- IL-10 Plays a Critical Role in Mitigating Acute Anaemia Development During African Trypanosome Infection.Pathogens (Basel, Switzerland) · 2025Article
- Household risk factors associated with canine leishmaniasis in Fortaleza, northeastern Brazil: Environmental, social, dog characteristics, and exposure to canineOne health (Amsterdam, Netherlands) · 2025Article
- Leishmania infantum-specific production of IL-17a in stimulated blood from dogs in different clinical stages of leishmaniosis.Parasites & vectors · 2025Article
- Unveiling prognostic indicators in canine leishmaniosis: two decades of evidence.Parasites & vectors · 2025Article
- An overview of host immune responses against Leishmania spp. infections.Human molecular genetics · 2025Review
- StandardizedVeterinary sciences · 2025Article
- Tick-borne coinfections modulate CD8Infection and immunity · 2025Article
- IL-12 and IFN-γ in Response to Leishmania Infantum Antigens in Felines From an Endemic Area for Visceral Leishmaniasis.Parasite immunology · 2025Article
- Preclinical evaluation of immunogenicity and protective efficacy of a recombinant chimeric protein vaccine against visceral leishmaniasis.Parasitology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Immune control of Leishmania infantum, the causative agent of most canine leishmaniosis (CanL), requires a balancing act between inflammatory and regulatory responses. This balance is specifically between the proinflammatory T helper 1 type (Th1) CD4+ T cells that are responsible for controlling parasite replication and T regulatory 1 cells which mediate an immunosuppressive, regulatory, response needed to dampen overabundant inflammation but if predominant, result in CanL progression. How this delicate immune cell interaction occurs in the dog will be highlighted in this review, focusing on the progressive changes observed within myeloid lineage cells (predominantly macrophages), B cells and T cells. After exposure to parasites, macrophages should become activated, eliminating L. infantum through release of reactive oxygen species. Unfortunately, multiple parasite and host factors can prevent macrophage activation allowing parasites to persist within them. T cells balance between a productive T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.